Latest Development Pipeline News

Finbar Group has confirmed the unconditional sale of its Rivervale development site for $13.68 million, with settlement expected by mid-October, boosting its H1 FY2026 earnings.

Summerset Group has achieved its highest-ever quarterly sales of occupation rights, driven by strong demand for care-related living options and steady growth beyond major cities.

Predictive Discovery Limited and Robex Resources Inc. have announced a merger to create a leading mid-tier gold producer in West Africa, targeting over 400,000 ounces of annual production by 2029 from a combined resource exceeding 9 million ounces.

Ramelius Resources has reported a substantial 38% increase in Mineral Resources and a remarkable 118% rise in Ore Reserves as of June 2025, underpinned by new project inclusions and a promising Pre-Feasibility Study for its Break of Day underground mine.

Lunnon Metals has reported promising drilling results at its Plentiful gold prospect, extending the mineralised structure to over 450 metres and revealing consistent widths and modest gold grades. These findings enhance the scale of opportunities within its Kambalda Gold & Nickel Project.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

Audalia Resources is raising $500,000 through a share placement to fund critical development and regulatory steps at its Medcalf Project, aiming to advance mining permits and design.

Aspen Group has entered a conditional contract to acquire the remaining stages of the Wallaroo Shores master planned community in South Australia for $14.1 million, significantly boosting its development pipeline in a fast-growing region.

Nimy Resources has initiated a $2.5 million Share Purchase Plan offering eligible shareholders shares at a 15.28% discount, aiming to fund key resource projects and working capital.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.